Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of AR101 in participants from prior AR101 trials
NL-OMON52762Phase 3Recruiting
- Sponsor
- Aimmune Therapeutics, Inc.
- Start
- May 2019
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of peanut protein in peanut allergy, sponsored by Aimmune Therapeutics, Inc. Primary endpoints: Frequency of adverse events, Frequency of premature discontinuation of AR101 dosing due to adverse events and 8 more. Started May 2019; status: recruiting.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NL-OMON52762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52762.